Endonovo Therapeutics (ENDV) Change in Account Payables (2018 - 2022)
Endonovo Therapeutics has reported Change in Account Payables over the past 8 years, most recently at $45554.0 for Q1 2022.
- Quarterly results put Change in Account Payables at $45554.0 for Q1 2022, up 117.88% from a year ago — trailing twelve months through Mar 2022 was -$17824.0 (down 112.93% YoY), and the annual figure for FY2021 was -$42470.0, down 145.08%.
- Change in Account Payables for Q1 2022 was $45554.0 at Endonovo Therapeutics, up from -$94579.0 in the prior quarter.
- Over the last five years, Change in Account Payables for ENDV hit a ceiling of $253290.0 in Q4 2019 and a floor of -$103719.0 in Q3 2018.
- Median Change in Account Payables over the past 5 years was $41497.0 (2019), compared with a mean of $35447.1.
- Biggest five-year swings in Change in Account Payables: surged 268.73% in 2019 and later tumbled 875.49% in 2021.
- Endonovo Therapeutics' Change in Account Payables stood at $113318.0 in 2018, then soared by 123.52% to $253290.0 in 2019, then plummeted by 95.18% to $12196.0 in 2020, then tumbled by 875.49% to -$94579.0 in 2021, then surged by 148.17% to $45554.0 in 2022.
- The last three reported values for Change in Account Payables were $45554.0 (Q1 2022), -$94579.0 (Q4 2021), and $41805.0 (Q3 2021) per Business Quant data.